Abstract| Volume 241, ISSUE 1, e197, July 2015

Impact of target-mediated elimination on evolocumab dose and regimen

      Aim: To investigate the PK/PD relationship between unbound evolocumab, unbound PCSK9, and LDL-C following evolocumab administration, and the impact of target-mediated drug disposition (TMDD) on dose and regimen.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect